Discovery of 6-(Aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2- α]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors

Journal of Medicinal Chemistry

Volumn 53, Issue 15, 2010, Pages 5620-5628

  Meng, Wei ^a   Brigance, Robert P ^a   Chao, Hannguang J ^a   Fura, Aberra ^a   Harrity, Thomas ^a   Marcinkeviciene, Jovita ^a   O'connor, Stephen P ^a   Tamura, James K ^a   Xie, Dianlin ^a   Zhang, Yaqun ^a   Klei, Herbert E ^a   Kish, Kevin ^a   Weigelt, Carolyn A ^a   Turdi, Huji ^a   Wang, Aiying ^a   Zahler, Robert ^a   Kirby, Mark S ^a   Hamann, Lawrence G ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (AMINOMETHYL) 5 (2,4 DICHLOROPHENYL) 7 METHYLIMIDAZO[1,2 A]PYRIMIDINE 2 CARBOXAMIDE DERIVATIVE; 6 (AMINOMETHYL) 5 (2,4 DICHLOROPHENYL) N (1 ETHYL 1H PYRAZOL 5 YL) 7 METHYLIMIDAZO[1,2 A]PYRIMIDINE 2 CARBOXAMIDE; [6 (AMINOMETHYL) 5 (2,4 DICHLOROPHENYL) 7 METHYLIMIDAZO[1,2 A]PYRIMIDIN 2 YL](MORPHOLINO)METHANONE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; IMIDAZOLE DERIVATIVE; POTASSIUM CHANNEL HERG; SODIUM CHANNEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; MOUSE; NONHUMAN; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIGENS, CD26; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DIABETES MELLITUS, TYPE 2; DOGS; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; HYPOGLYCEMIC AGENTS; IMIDAZOLES; MALE; MICE; MICE, OBESE; MODELS, MOLECULAR; PYRIMIDINES; RATS; SODIUM CHANNEL BLOCKERS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77955387970     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100634a     Document Type: Article

References (43)

1. Wideman, R. D.; Kieffer, T. J. Mining incretin hormone pathways for novel therapies Trends Endocrinol. Metab. 2009, 20, 280-286
2. Triplitt, C.; Wright, A.; Chiquette, E. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus Pharmacotherapy 2006, 26, 360-374
3. Gallwitz, B. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus Treat. Endocrinol. 2005, 4, 361-370 (Pubitemid 41751172)
4. Holst, J. J. Glucagon-like peptide-1 (GLP-1) a newly discovered GI hormone Gastroenterology 1994, 107, 1048-1055
5. Drucker, D. J. Glucagon-like peptides Diabetes 1998, 47, 159-169
6. Vilsboll, T.; Holst, J. J. Incretins, insulin secretion and type 2 diabetes mellitus Diabetologia 2004, 47, 357-366
7. Elahi, D.; McAloon-Dyke, M.; Fukagawa, N. K.; Meneilly, G. S.; Sclater, A. L.; Minaker, K. L.; Habener, J. F.; Andersen, D. K. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects Regul. Pept. 1994, 51, 63-75
8. Nauck, M. A.; Bartels, E.; Oerskov, C.; Ebert, R.; Creutzfeldt, W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations J. Clin. Endocrinol. Metab. 1993, 76, 912-917
9. Gentilella, R.; Bianchi, C.; Rossi, A.; Rotella, C. M. Exenatide: A review from pharmacology to clinical practice Diabetes, Obes. Metab. 2009, 11, 544-556
10. Gonzalez, C.; Beruto, V.; Keller, G.; Santoro, S.; Di Girolamo, G. Investigational treatments for type 2 diabetes mellitus: Exenatide and Liraglutide Expert Opin. Invest. Drugs 2006, 15, 887-895
11. Holst, J. J. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1 Diabetes Metab. Res. Rev. 2002, 18, 430-441
12. Hansen, L.; Deacon, C. F.; Orskov, C.; Holst, J. J. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine Endocrinology 1999, 140, 5356-5363
13. Nagakura, T.; Yasuda, N.; Yamazaki, K.; Ikuta, H.; Yoshikawa, S.; Asano, O.; Tanaka, I. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats Biochem. Biophys. Res. Commun. 2001, 284, 501-506
14. Marguet, D.; Baggio, L.; Kobayashi, T.; Bernard, A.; Pierres, M.; Nielsen, P. F.; Ribel, U.; Watanabe, T.; Drucker, D. J.; Wagtmann, N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26 Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 6874-6879
15. Durinx, C.; Lambeir, A.; Bosmans, E.; Falmagne, J.; Berghmans, R.; Haemers, A.; Scharpe, S.; De Meester, I. Molecular characterization of dipeptidyl peptidase activity in serum. Soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides Eur. J. Biochem. 2000, 267, 5608-5613
16. Iwaki-Egawa, S.; Watanabe, Y.; Kikuya, Y.; Fujimoto, Y. Dipeptidyl peptidase IV from human serum: purification, characterization, and N-terminal amino acid sequence J. Biochem. 1998, 124, 428-433
17. Villhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Burkey, B. F.; Dunning, B. E.; Prasad, K.; Mangold, B. L.; Russell, M. E.; Hughes, T. E. 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties J. Med. Chem. 2003, 46, 2774-2789
18. Kim, D.; Wang, L.; Beconi, M.; Eiermann, G. J.; Fisher, M. H.; He, H.; Hickey, G. J.; Kowalchick, J. E.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M. E.; Patel, R. A.; Petrov, A.; Scapin, G.; Patel, S. B.; Roy, R. S.; Wu, J. K.; Wyvratt, M. J.; Zhang, B. B.; Zhu, L.; Thornberry, N. A.; Weber, A. E. (2 R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3- a ]pyrazin-7(8 H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J. Med. Chem. 2005, 48, 141-151
19. Augeri, D. J.; Robl, J. A.; Betebenner, D. A.; Magnin, D. R.; Khanna, A.; Robertson, J. G.; Wang, A.; Simpkins, L. M.; Taunk, P.; Huang, Q.; Han, S. P.; Abboa-Offei, B.; Cap, M.; Xin, L.; Tao, L.; Tozzo, E.; Welzel, G. E.; Egan, D. M.; Marcinkeviciene, J.; Chang, S. Y.; Biller, S. A.; Kirby, M. S.; Parker, R. A.; Hamann, L. G. Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of Type 2 diabetes J. Med. Chem. 2005, 48, 5025-5037
20. Feng, J.; Zhang, Z.; Wallace, M. B.; Stafford, J. A.; Kaldor, S. W.; Kassel, D. B.; Navre, M.; Shi, L.; Skene, R. J.; Asakawa, T.; Takeuchi, K.; Xu, R.; Webb, D. R.; Gwaltney, S. L. Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV J. Med. Chem. 2007, 50, 2297-2300
21. For other small molecular DPP4 inhibitors, see Havale, S. H.; Pal, M. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes Bioorg. Med. Chem. 2009, 17, 1783-1802 and references cited therein.
22. Brigance, R. P.; Meng, W.; Fura, A.; Harrity, T.; Wang, A.; Zahler, R.; Kirby, M. S.; Hamman, L. G. Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes. Bioorg. Med. Chem. Lett. 2010, 20, 4395 - 4398.
23. Abignente, E.; Sacchi, A.; Laneri, S.; Rossi, F.; D'Amico, M.; Berrino, L.; Calderaro, V.; Parrillo, C. Research on heterocyclic compounds. XXXII. Synthesis and cyclooxygenase-independent antiinflammatory and analgesic activity of imidazo[1,2- a ]pyrimidine derivatives Eur. J. Med. Chem. 1994, 29, 279-286
24. Commercon, A. Preparation of bis(N -protected)-2-aminoimidazole-4- carboxaldehyde. Fr. Demande 1993, 12 pp. FR 2681323.
25. Box, K.; Comer, J.; Huque, F. Correlations between PAMPA permeability and log P. In Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, And Computational Strategies; Testa, B., Ed.; Verlag Helvetica Chimica Acta: Zurich, Switzerland, 2006; pp 243 - 257.
26. Abbott, C. A.; Yu, D. M. T.; Woollatt, E.; Sutherland, G. R.; McCaughan, G. W.; Gorrell, M. D. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8 Eur. J. Biochem. 2000, 267, 6140-6150
27. Bjelke, J., R.; Christensen, J.; Nielsen, P., F.; Branner, S.; Kanstrup, A. B.; Wagtmann, N.; Rasmussen, H. B. Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV Biochem. J. 2006, 396, 391-399
28. Olsen, C.; Wagtmann, N. Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV Gene 2002, 299, 185-193
29. Ajami, K.; Abbott, C., A.; McCaughan, G., W.; Gorrell, M., D. Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity Biochim. Biophys. Acta 2004, 1679, 18-28
30. Maes, M. B.; Lambeir, A. M.; Gilany, K.; Senten, K.; Van der veken, P.; Leiting, B.; Augustyns, K.; Scharpe, S.; De Meester, I. Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7) Biochem. J. 2005, 386, 315-324
31. Araki, H.; Li, Y. H.; Yamamoto, Y.; Haneda, M.; Nishi, K.; Kikkawa, R.; Ohkubo, I. Purification, molecular cloning, and immunohistochemical localization of dipeptidyl peptidase II from the rat kidney and its identity with quiescent cell proline dipeptidase J. Biochem. 2001, 129, 279-288
32. Gorrell, M. D.; Yu, D. M. T. Diverse functions in a conserved structure: the dipeptidyl peptidase IV gene family. In Trends in Protein Research; Robinson, J. W., Ed.; Nova Science Publishers, Inc.: Hauppauge, NY, 2005; pp 1 - 78.
33. Edosada, C. Y.; Quan, C.; Wiesmann, C.; Tran, T.; Sutherlin, D.; Reynolds, M.; Elliott, J. M.; Raab, H.; Fairbrother, W.; Wolf, B. B. Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity J. Biol. Chem. 2006, 281, 7437-7444
34. Burkey, B. F.; Hoffmann, P. K.; Hassiepen, U.; Trappe, J.; Juedes, M.; Foley, J. E. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited Diabetes Obes. Metab. 2008, 10, 1057-1061
35. Lankas, G. R.; Leiting, B.; Roy, R. S.; Eiermann, G. J.; Beconi, M. G.; Biftu, T.; Chan, C. C.; Edmondson, S.; Feeney, W. P.; He, H.; Ippolito, D. E.; Kim, D.; Lyons, K. A.; Ok, H. O.; Patel, R. A.; Petrov, A. N.; Pryor, K. A.; Qian, X.; Reigle, L.; Woods, A.; Wu, J. K.; Zaller, D.; Zhang, X.; Zhu, L.; Weber, A. E.; Thornberry, N. A. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes. Potential importance of selectivity over dipeptidyl peptidases 8 and 9 Diabetes 2005, 54, 2988-2994
36. Aronov, A. M. Predictive in silico modeling for hERG channel blockers Drug Discovery Today 2005, 10, 149-155
37. Song, M.; Clark, M. Development and evaluation of an in silico model for hERG binding J. Chem. Inf. Model 2006, 46, 392-400
38. Vaz, R. J.; Li, Y.; Rampe, D. Human ether-a-go-go related gene (HERG): A chemist's perspective Prog. Med. Chem. 2005, 43, 1-18
39. The X-ray crystal structure coordinates of 24c (BMS-762382) in DPP4 are deposited in the Protein Data Bank (PDB code 3NOX).
40. Metzler, W. J.; Yanchunas, J.; Weigelt, C.; Kish, K.; Klei, H. E.; Xie, D.; Zhang, Y.; Corbett, M.; Tamura, J. K.; He, B.; Hamann, L. G.; Kirby, M. S.; Marcinkeviciene, J. Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation Protein Sci. 2008, 17, 240-250
41. Thoma, R.; Loffler, B.; Stihle, M.; Huber, W.; Ruf, A.; Hennig, M. Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV Structure 2003, 11, 947-959
42. Engel, M.; Hoffmann, T.; Wagner, L.; Wermann, M.; Heiser, U.; Kiefersauer, R.; Huber, R.; Bode, W.; Demuth, H.-U.; Brandstetter, H. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 5063-5068
43. Kirby, M.; Yu, D. M. T.; O'Connor, S. P.; Gorrell, M. D. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition Clin. Sci. 2010, 118, 31-41